This is a regulatory disclosure made to the BSE Limited and the National Stock Exchange of India Limited. The purpose of the document is to intimate the exchanges about an upcoming meeting of the Board of Directors of Astec LifeSciences Limited.
The Board meeting is scheduled to be held on Monday, 26th October, 2026. The primary agenda for the meeting is to consider and approve the company's Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2026.
The disclosure states that these financial results will be presented to the Board only after they have been reviewed by the company's Audit Committee. This intimation is made as a mandatory compliance requirement under Regulations 29 and 50(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The document was signed by Tejashree Pradhan, Company Secretary & Compliance Officer (FCS 7167), on behalf of Astec LifeSciences Limited. A copy of this intimation is also available on the company's website at www.godrejastec.com.
Financial Impact: The disclosure is an intimation of a scheduled meeting and does not contain any financial figures, results, or guidance. The financial impact will be known only after the board meeting on 26th October 2026.